natgillin/translations-raw huggingface dataset:
Although most subjects recovered without sequelae, deaths associated with overdoses of bupropion alone have been reported in subjects ingesting large doses of the drug.
Iako se većina ispitanika oporavila bez posljedica, smrti povezane s predoziranjem samo bupropionom su prijavljene u ispitanika koji su uzeli velike doze lijeka.
• At the request of the European Medicines Agency;
Ažurirani RMP treba dostaviti: • Na zahtjev Europske agencije za lijekove;
INFORMATION IN BRAILLE mysimba
16. PODACI NA BRAILLEOVOM PISMU mysimba
The types of tolerability events were similar to the events observed in patients with normal renal function (see sections 4.2, 4.4, and 5.2).
Vrste događaja podnošljivosti su bile slične događajima uočenih kod bolesnika s normalnom funkcijom bubrega (vidjeti dijelove 4.2, 4.4, i 5.2).
• Patients with uncontrolled hypertension (see section 4.4)
• Bolesnici s nekontroliranom hipertenzijom (vidjeti dio 4.4)
• tramadol (a painkiller belonging to the class of opiates);
• tramadol (lijek protiv boli koji pripada skupini opijata);
The relevance of these observations to human fertility is not known.
Važnost tih opažanja za ljudsku plodnost nije poznata.
Other sources of information
Drugi izvori i informacija
If you feel depressed, contemplate suicide, have a history of attempting suicide or any other mental health problems, you should inform your doctor before taking this medicine.
Ako se osjećate depresivno, razmišljate o samoubojstvu, imate povijest pokušaja samoubojstva ili imate neki drugi problem mentalnog zdravlja, morate obavijestiti svog liječnika prije nego uzmete ovaj lijek.
Although citalopram is not primarily metabolised by CYP2D6, in one study, bupropion increased the Cmax and AUC of citalopram by 30% and 40%, respectively.
Iako se citalopram primarno ne metabolizira preko CYP2D6, u jednom ispitivanju, bupropion je povećao Cmax i AUC citaloprama za 30 % odnosno 40 %.
If you have a fit (seizure), you should stop taking Mysimba and consult your doctor immediately.
Ako imate napadaje, morate prestati uzimati lijek Mysimba i odmah se obratiti liječniku.
Use of naltrexone / bupropion with other OCT2 substrates (e.g., metformin) in clinical trials did not indicate the need for dose adjustment or other precautions.
Uporaba naltrekson / bupropiona s drugim OCT2 supstratima (npr. metformin) u kliničkim ispitivanjima nisu ukazala na potrebu za prilagodbom doze ili drugim mjerama opreza.
Based on these results, there are no dose adjustments recommended for patients with mild renal impairment.
Na temelju ovih rezultata, ne preporučuje se prilagodba doze za bolesnike s blagim oštećenjem bubrega.
Patients with type 2 diabetes may be more prone to these events due to concomitant medicinal product use (e.g., metformin) or may be more likely to have underlying gastrointestinal disorders (e.g., gastroparesis) predisposing to gastrointestinal symptoms.
Bolesnici s dijabetesom tipa 2 mogu biti skloniji tim događajima, zbog istodobne uporabe lijekova (npr. metformin) ili je vjerojatnije da imaju podležeće gastrointestinalne poremećaje (npr. gastropareza) koji ih čine podložnim za gastrointestinalne simptome.
The study is to be monitored regularly by a Data Monitoring Committee (DMC).
Ispitivanje će biti nadzirano od strane Povjerenstva za nadzor podataka (engl.
Frequency of the side effects suicide attempts, suicidal behavior, suicidal thoughts and feeling depressed are not known and cannot be estimated from the available data in people taking Mysimba.
Učestalost nuspojava pokušaja samoubojstva, suicidalnog ponašanja i suicidalnih misli te osjećaja depresije nije poznata i ne može se procijeniti iz dostupnih podataka kod osoba koje uzimaju lijek Mysimba.
• you have uncontrolled coronary artery disease (a heart disease caused by poor blood flow in the blood vessels of the heart) with symptoms such as angina (characterised by chest pain) or a recent heart attack.
• ako imate nekontroliranu bolest koronarnih arterija (bolest srca uzrokovana lošim protokom krvi u krvnim žilama srca) sa simptomima kao što su angina (karakterizirana bolom u prsištu) ili nedavni srčani udar.
* Difference from placebo, p<0.001.
* Razlika od placeba, p< 0,001
The mean volume of distribution at steady state of oral naltrexone and bupropion given as naltrexgone / bupropion, Vss/F, was 5697 liters and 880 liters, respectively.
Srednja vrijednost volumena distribucije u stanju dinamičke ravnoteže oralnog naltreksona i bupropiona danih kao naltrekson / bupropion, Vss/F, bila je 5697 litara odnosno 880 litara.
• Week 4 and onwards: Two tablets in the morning and two tablets in the evening The maximum recommended daily dose of Mysimba is two tablets taken twice daily for a total dose of 32 mg naltrexone hydrochloride and 360 mg bupropion hydrochloride.
• 4. tjedan i nadalje: dvije tablete ujutro i dvije tablete navečer Maksimalna preporučena dnevna doza lijeka Mysimba je dvije tablete uzete dva puta na dan za ukupnu dozu od 32 mg naltreksonklorida i 360 mg bupropionklorida.
Clinical studies of naltrexone / bupropion did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.
Klinička ispitivanja naltrekson / bupropiona nisu uključila dovoljan broj ispitanika u dobi od 65 godina i više kako bi se utvrdilo da li oni imaju drugačiji odgovor na lijek u odnosu na mlađe ispitanike.
• steroids (except drops, creams, or lotions for eye and skin conditions or inhalers for breathing disorders such as asthma);
• steroidi (osim kapi, krema, ili losiona za oči i stanja kože ili inhalatori za poremećaje disanja poput astme);
Naltrexone / bupropion should preferably be taken with food, as it is known that both naltrexone and bupropion plasma concentrations are increased with food and the safety and efficacy data from clinical trials is based on dosing with food.
Naltrekson / bupropion je bolje uzimati s hranom, jer je poznato da se koncentracije u plazmi i naltreksona i bupropiona povećavaju s hranom i jer se podaci o sigurnosti i djelotvornosti iz kliničkih ispitivanja temelje na doziranju s hranom.
A meta-analysis of placebo-controlled clinical trials of antidepressants in adult subjects with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in subjects less than 25 years old.
Meta analiza placebom kontroliranih kliničkih ispitivanja antidepresiva u odraslih ispitanika s psihijatrijskim poremećajima su pokazala povećan rizik od suicidalnog ponašanja s antidepresivima u usporedbi s placebom u ispitanika mlađih od 25 godina.
Naltrexone / bupropion (-3.7%) was significantly (p<0.001) more efficacious than placebo (-1.7%) treatment in this population.
Naltrekson / bupropion (-3,7 %) je bio značajno (p < 0,001) djelotvorniji u te populacije nego placebo (-1,7 %).
The ≥5% weight loss threshold at Week 16 had 86.4% positive predictive value and 84.8% negative predictive value for determining whether a subject treated with naltrexone / bupropion would achieve at least 5% weight loss at Week 56.
Prag gubitka težine od ≥ 5 % 16. tjedna je imao pozitivnu prediktivnu vrijednost od 86,4% i negativnu prediktivnu vrijednost od 84,8 % za određivanje da li bi ispitanik liječen s naltrekson / bupropionom postigao barem 5 % gubitak tjelesne težine u 56. tjednu.
If you have thoughts about harming yourself or other distressing thoughts, or if you are depressed and notice that you feel worse or develop new symptoms, contact your doctor or go to a hospital straight away.
Ako razmišljate o samoozljeđivanju ili imate uznemirujuće misli, ili ako ste deprimirani i osjećajte se lošije ili su se pojavili novi simptomi, odmah se obratite svom liječniku ili se javite u bolnicu
Pharmacotherapeutic group: A08AA Centrally acting antiobesity products, ATC code: A08AA62 bupropion and naltrexone.
Farmakoterapijska skupina: A08AA Lijekovi protiv pretilosti koji djeluju centralno, ATK oznaka: A08AA62 bupropion i naltrekson.
Electrocardiogram change (N)
Srčani poremećaji često promjene u elektrokardiogramu (N)
In vitro findings suggest that CYP2B6 is the principal isozyme involved in the formation of hydroxybupropion, while CYP1A2, 2A6, 2C9, 3A4 and 2E1 are less involved.
In vitro rezultati sugeriraju da je CYP2B6 glavni izoenzim koji sudjeluje u stvaranju hidroksibupropiona, a CYP1A2, 2A6, 2C9, 3A4 i 2E1 su manje uključeni.
If patients experience clinically relevant and sustained increases in blood pressure or pulse rate as a result of naltrexone / bupropion treatment, it should be discontinued.
Ako bolesnici doživljavaju klinički relevantno i produljeno povišenje krvnog tlaka ili brzine pulsa kao rezultat liječenja naltrekson / bupropionom, treba ga prekinuti.
Since there is limited information on the systemic exposure to naltrexone and bupropion in infants/newborns being breast-fed, a risk to the newborns/infants cannot be excluded.
Budući da su informacije o sistemskoj izloženosti naltreksonu i bupropionu u dojenčadi / novorođenčadi koja se doji ograničene, rizik za novorođenčad / dojenčad se ne može isključiti.
M.S. Jacovides & Co Ltd Tel: 800 90 819
Jacovides & Co Ltd Tel: 800 90 819
In a series of studies in healthy volunteers, ritonavir (100 mg twice daily or 600 mg twice daily) or ritonavir 100 mg plus lopinavir 400 mg twice daily reduced the exposure of bupropion and its major metabolites in a dose dependent manner by 20 to 80%.
U nizu ispitivanja u zdravih dobrovoljaca, ritonavir (100 mg dva puta dnevno ili 600 mg dva puta dnevno) ili ritonavir 100 mg plus lopinavir 400 mg dva puta dnevno smanjili su izloženost bupropionu i njegovom glavnom metabolitu u ovisnosti o dozi od 20 do 80 %.
*** Toothache and dental caries, while not meeting the criteria for inclusion in this table, are listed based on the subset of patients with dry mouth, in which a higher incidence of toothache and dental caries was observed in subjects treated with NB versus placebo.
*** Zubobolja i zubni karijes, iako ne ispunjavaju kriterije za uključivanje u ovu tablicu, navedeni su na temelju podskupine bolesnika sa suhim ustima, u kojoj se uočila veća incidencija zubobolje i zubnog karijesa u ispitanika liječenih sa NB naspram placeba.
Alternatively, treatment cessation might be considered (see sections 4.7 and
Kao druga mogućnost, može se razmotriti prestanak liječenja (vidjeti dijelove 4.7 i 4.8).
The two co-primary endpoints were percent change from baseline body weight and the proportion of subjects achieving ≥5% total decreased body weight.
Dva koprimarna ishoda su bili postotak promjene od početne tjelesne težine i udio ispitanika koji su postigli ukupno smanjenu tjelesnu težinu od ≥ 5 %.
Attempt to overcome blockade: The attempt to overcome any naltrexone opioid blockade by administering large amounts of exogenous opioids is very dangerous and may lead to a fatal overdose or life endangering opioid intoxication (e.g., respiratory arrest, circulatory collapse).
Pokušaj prevladavanja bilo koje blokade opioida naltreksonom primjenom velikih količina egzogenih opioida je vrlo opasna i može dovesti do fatalnog predoziranja ili po život opasne intoksikacije opioidima (npr. respiratorni arest, cirkulatorni kolaps).
The initial dose is usually one tablet (8 mg naltrexone hydrochloride / 90 mg bupropion hydrochloride) once a day in the morning.
Početna doza je obično jedna tableta (8 mg naltreksonklorida / 90 mg bupropionklorida) jedanput na dan ujutro.
Naltrexone / bupropion has not been studied in conjunction with alpha-adrenergic blockers or clonidine.
Naltrekson / bupropion nije ispitivan zajedno s alfa-adrenergičkim blokatorima ili klonidinom.
Elderly people: The pharmacokinetics of naltrexone / bupropion have not been evaluated in the elderly population.
Starije osobe: Farmakokinetika naltrekson / bupropiona nije procijenjena u starijoj populaciji.
Acne, Erythema multiforme and Stevens Johnson syndrome
- Multiformni eritem i Stevens-Johnsonov sindrom
* Difference from placebo, p<0.001 ** Difference from placebo, p<0.01
* Razlika od placeba, p < 0,001 ** Razlika od placeba, p < 0,01
The treatment effects observed in obese and overweight subjects with type 2 diabetes mellitus (Study NB-304) were somewhat less pronounced than those observed in the other Phase 3 studies.
Učinci liječenja uočeni u pretilih ispitanika i ispitanika s prekomjernom težinom i s dijabetes melitusom tipa 2 (ispitivanje NB-304) bili su nešto manje izraženi od onih uočenih u drugim ispitivanjima faze 3.
• Medicines used in the treatment of HIV infection and AIDS, such as efavirenz and ritonavir;
• lijekovi koji se koriste u liječenju HIV infekcije i SIDA-e, kao što su efavirenz i ritonavir;
Patients should be cautioned about driving or operating hazardous machinery in case naltrexone/bupropion may affect their ability to engage in such activities (see sections 4.4 and 4.8)
Bolesnike treba upozoriti vezano uz upravljanje vozilima ili rad sa opasnim strojevima za slučaj da naltrekson / bupropion možda u njih bude utjecao na sposobnost sudjelovanja u takvim aktivnostima (vidjeti dijelove 4.4 i 4.8)
Similar clinical drug interactions resulting in increased pharmacokinetic exposure of CYP2D6 substrates have also been observed with bupropion as a single medicinal product with desipramine and venlafaxine.
Slične kliničke interakcije lijekova s posljedičnom povišenom farmakokinetičkom izloženošću supstrata CYP2D6, također su uočena s bupropionom kao jedinim lijekom uz desipramin i venlafaksin.
Blocking this inhibitory feedback loop with naltrexone is proposed to facilitate a more potent and longer-lasting activation of POMC neurons, thereby amplifying the effects of bupropion on energy balance.
Smatra se da blokiranje ove inhibitorne povratne sprege s naltreksonom omogućava potentniju i dugotrajniju aktivaciju POMC neurona, čime se pojačava učinak bupropiona na energetsku bilancu.
The most serious clinical implications of combined use of bupropion and naltrexone overdose are likely related to bupropion.
Najozbiljnije kliničke implikacije kombinirane uporabe prekomjerne doze bupropiona i naltreksona vjerojatno su povezane s bupropionom.
Naltrexone and 6-beta-naltrexol are not metabolised by cytochrome P450 enzymes and in vitro studies indicate that there is no potential for inhibition or induction of important isozymes.
Naltrekson i 6-beta-naltreksol se ne metaboliziraju putem enzima citokroma P450 i in vitro ispitivanja pokazuju da ne postoji mogućnost za inhibiciju ili indukciju važnih izoenzima.
- Rhabdomyolysis
- Rabdomioliza
Therefore, mild increases in creatinine observed after long-term treatment with naltrexone / bupropion are likely due to inhibition of OCT2 and not indicative of changes in creatinine clearance.
Dakle, blaga povećanja kreatinina uočena nakon dugotrajnog liječenja s naltrekson / bupropionom su vjerojatno posljedica inhibicije OCT2 i ne ukazuju na promjene u klirensu kreatinina.
Bupropion and its metabolites competitively inhibit the OCT2 in the basolateral membrane of the renal tubule responsible for creatinine secretion, in a manner similar to the OCT2 substrate cimetidine.
OCT2 supstrati Bupropion i njegovi metaboliti kompetitivno inhibiraju OCT2 u bazolateralnoj membrani bubrežnih tubula odgovornih za lučenje kreatinina, na način sličan OCT2 supstratu cimetidinu.
Patients must be advised to exercise caution while driving or operating machines during treatment with naltrexone/bupropion, especially at the beginning of the treatment or during the titration phase.
Bolesnicima treba savjetovati oprez prilikom upravljanja vozilima ili rada sa strojevima tijekom liječenja naltrekson / bupropionom, posebice na početku liječenja ili tijekom faze titracije.
Following oral administration of 200 mg of 14C-bupropion hydrochloride in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively.
Nakon peroralne primjene 200 mg 14C-bupropionklorida u ljudi, 87 % i 10 % radioaktivne doze su pronađene u urinu odnosno fecesu.
However, approximately 12% of subjects took a concomitant opioid or opioid-like medicinal product while enrolled in the naltrexone / bupropion clinical studies, the majority of whom continued study treatment without interruption of naltrexone / bupropion dose, without untoward consequences.
Ipak, oko 12 % ispitanika je uzelo istodobno opioide ili lijekove nalik opioidima dok su sudjelovali u kliničkim ispitivanjima s naltrekson / bupropionom, od kojih je većina nastavila liječenje u ispitivanju bez prekida doze naltrekson / bupropiona i bez nepovoljnih posljedica.
No events of dizziness, dry mouth, headache, or insomnia in subjects treated with naltrexone / bupropion were considered serious.
Niti jedan događaj omaglice, suhih usta, glavobolje ili nesanice u ispitanika liječenih s naltrekson/bupropionom nije smatran ozbiljnim.
In clinical studies, 23.8% of subjects receiving naltrexone / bupropion and 11.9% of subjects receiving placebo discontinued treatment due to an adverse event.
U kliničkim ispitivanjima, 23,8 % ispitanika koji su primali naltrekson / bupropion i 11,9 % ispitanika koji su primali placebo, prekinulo je liječenje zbog nuspojava.
Dose reduction is not necessary in patients with mild renal impairment.
Smanjenje doze nije potrebno za bolesnike s blagim oštećenjem bubrega.
Human overdose experience
Iskustvo predoziranja u ljudi
The medicinal product has two components: naltrexone, a mu-opioid antagonist, and bupropion, a weak inhibitor of neuronal dopamine and norepinephrine reuptake.
Lijek ima dvije sastavnice: naltrekson, mu-opioidni antagonist i bupropion, slabi inhibitor ponovne pohrane dopamina i norepinefrina u neuronima.
Patients should be aware that they may be more sensitive to lower doses of opioids after naltrexone / bupropion treatment is discontinued.
Bolesnici moraju biti svjesni da mogu biti osjetljiviji na niže doze opioida nakon prekida liječenja s naltrekson / bupropionom.
Administration of naltrexone / bupropion with inhibitors or inducers of UGT 1A2 and 2B7 should be undertaken with caution as these may alter the exposure of naltrexone.
Primjenu naltrekson / bupropiona s inhibitorima ili induktorima UGT 1A2 i 2B7 treba provoditi s oprezom, jer ti lijekovi mogu promijeniti izloženost naltreksonu.
The fraction of the oral dose of bupropion excreted unchanged was 0.5%, a finding consistent with the extensive metabolism of bupropion.
Frakcija oralne doze bupropiona od 0,5 % izlučuje se nepromijenjeno, što je u skladu s opsežnim metabolizmom bupropiona.
What you need to know before you take Mysimba
Što morate znati prije nego počnete uzimati lijek Mysimba
Mysimba with alcohol
Lijek Mysimba s alkoholom
The potential exists for a drug interaction between naltrexone / bupropion and drugs that induce or are substrates of the CYP2B6 isozyme.
Postoji potencijal interakcije između naltrekson / bupropiona i lijekova koji induciraju ili su supstrati za CYP2B6 izoenzim.
Naltrexone / bupropion has influence on the ability to drive and use machines.
Naltrekson / bupropion utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Due to the antagonistic effect of naltrexone at the opioid receptor, patients taking naltrexone / bupropion may not fully benefit from treatment with opioid-containing medicinal products, such as cough and cold remedies, antidiarrhoeal preparations and opioid analgesics.
Zbog antagonističkog učinka naltreksona na opioidni receptor, bolesnici koji uzimaju naltrekson / bupropion možda neće imati potpunu korist od liječenja s lijekovima koji sadrže opioide kao što su lijekovi protiv kašlja i prehlade, pripravci protiv proljeva i opioidni analgetici.
If naltrexone / bupropion is added to the treatment regimen of a patient already receiving a drug metabolised by CYP2D6, the need to decrease the dose of the original medicinal product should be considered, particularly for those concomitant medicinal products with a narrow therapeutic index.
Ako se naltrekson / bupropion dodaje režimu liječenja bolesnika koji već prima lijek metaboliziran putem CYP2D6, mora se razmotriti smanjenje doze prvotnog lijeka i to naročito za istodobno uzimane lijekove s uskim terapijskim indeksom.
There are no known pharmacokinetic interactions between naltrexone and alcohol.
Nema poznatih farmakokinetičkih interakcija između naltreksona i alkohola.
Caution should be used when prescribing naltrexone / bupropion to patients with predisposing factors that may increase the risk of seizure including:
Treba biti oprezan kod propisivanja naltrekson / bupropiona bolesnicima sa predisponirajućim čimbenicima koji mogu povećati rizik od napadaja, uključujući:
CI, Confidence Interval; LS, Least Squares.
CI, Interval pouzdanosti; LS (engl.
Do not take Mysimba with:
Nemojte uzimati lijek Mysimba s:
In the arcuate nucleus of the hypothalamus, bupropion stimulates pro-opiomelanocortin (POMC) neurons that release alpha-melanocyte stimulating hormone (α-MSH), which in turn binds to and stimulates melanocortin 4 receptors (MC4-R).
U arkuatnoj jezgri hipotalamusa, bupropion stimulira neurone pro-opiomelanokortina (engl. pro opiomelanocortin, POMC) koji otpuštaju alfa-hormon koji stimulira melanocite (engl. alpha melanocyte stimulating hormone, α-MSH), koji se zatim veže na i potiče melanokortin 4 receptore
Fasting glucose, mg/dL
HDL-K, mg/dL
Submission of the protocol by 31 March
Dostaviti protokol ispitivanja do 31. ožujka 2015.
Due to these reasons, naltrexone / bupropion should be used with caution in patients over 65 years of age and is not recommended in patients over 75 years of age.
Zbog tih razloga, naltrekson / bupropion treba koristiti s oprezom u bolesnika starijih od 65 godina, a ne preporučuje se u bolesnika starijih od 75 godina.
Of the overall population of 4,536 subjects in the naltrexone / bupropion Phase 3 studies, 25% had hypertension, 33% had fasting glucose levels ≥100 mg/dL (5.6 mmol/L) at baseline, 54% had dyslipidaemia at study entry, and 11% had type 2 diabetes.
Od ukupne populacije od 4536 ispitanika u ispitivanju faze 3 s naltrekson / bupropionom, 25 % je imalo hipertenziju, 33 % je imalo razinu glukoze na tašte ≥ 100 mg / dL (5,6 mmol / L) na početku, 54 % je imalo dislipidemiju pri uključivanju u ispitivanje, i 11 % je imalo dijabetes tipa 2.
Accumulation:
Akumulacija:
Although in placebo-controlled clinical trials with naltrexone / bupropion for the treatment of obesity in adult subjects, no suicides or suicide attempts were reported in studies up to 56 weeks duration with naltrexone / bupropion, suicidality events (including suicidal ideation) have been reported in subjects of all ages treated with naltrexone / bupropion post-marketing.
Iako u placebom kontroliranim kliničkim ispitivanjima s naltreksonom / bupropionom za liječenje pretilosti u odraslih ispitanika, nisu zabilježena samoubojstva ili pokušaji samoubojstva u ispitivanjima do 56 tjedana s naltreksonom / bupropionom, suicidalni događaji (uključujući suicidalne ideje) su prijavljeni u ispitanika svih dobnih skupina liječenih naltreksonom / bupropionom nakon stavljanja lijeka u promet.
Clinical experience included varying prandial conditions and supports the use of naltrexone / bupropion tablets with food.
Kliničko iskustvo uključuje različite uvjete obroka i podupiru uporabu tableta naltrekson / bupropiona s hranom.
Greater HbA1c improvement compared to placebo was observed at the first post-baseline measurement (Week 16, p<0.001).
Veće poboljšanje HbA1c u odnosu na placebo uočeno je u prvom mjerenju nakon početnog (16. tjedan, p
Type 2 diabetes
Dijabetes tipa 2
The list of terms in Table 2 provides information on the adverse reactions of the individual components naltrexone (N) and bupropion (B) identified in their respective approved SmPCs for different indications.
Popis pojmova u tablici 2 pruža informacije o nuspojavama pojedinačnih sastavnica naltreksona (N) i bupropiona (B) identificiranih u njihovim odobrenim Sažecima opisa svojstava lijeka za različite indikacije.
The body mass index is calculated as the measured body weight (kg) divided by the measured height squared (m2).
Indeks tjelesne mase izračunava se kao izmjerena tjelesna težina (kg)